Marked increase in CYP24A1 gene expression in human papillary thyroid cancer

Thyroid

Volumn 21, Issue 4, 2011, Pages 459-460

  Balla, Bernadett ^a   Kósa, János P ^a   Tobiás, Bálint ^a   Halászlaki, Csaba ^a   Takács, István ^a   Horváth, Henrik ^a   Speer, Gábor ^a   Nagy, Zsolt ^a   Horányi, János ^a   Járay, Balázs ^a   Székely, Eszter ^a   Lakatos, Péter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COLECALCIFEROL; CYTOCHROME P450; CYTOCHROME P450 24A1; MESSENGER RNA; OXYGENASE; UNCLASSIFIED DRUG;

CANCER CELL CULTURE; CANCER INHIBITION; CAUCASIAN; GENE ACTIVITY; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN TISSUE; HUNGARY; LETTER; PRIORITY JOURNAL; RNA ISOLATION; THYROID PAPILLARY CARCINOMA; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RNA, MESSENGER; STEROID HYDROXYLASES; THYROID NEOPLASMS;

EID: 79954510823     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0420     Document Type: Letter

References (11)

1. Chung M, Balk EM, Brendel M, Ip S, Lau J, Lee J, Lichten-stein A, Patel K, Raman G, Tatsioni A, Terasawa T, Trika-linos TA 2009 Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess 183:1-420.
2. Krishnan AV, Trump DL, Johnson CS, Feldman D 2010 The role of vitamin D in cancer prevention and treatment. Endocrinol Metab Clin North Am 39:401-418.
3. Kriebitzsch C, Verlinden L, Eelen G, Tan BK, Van Camp M, Bouillon R, Verstuyf A 2009 The impact of 1,25(OH)2D3 and its structural analogs on gene expression in cancer cells\a microarray approach. Anticancer Res 29:3471-3483.
4. Horváth HC, Lakatos P, Kósa JP, Bácsi K, Borka K, Bises G, Nittke T, Hershberger PA, Speer G, Kállay E 2010 The can-didate oncogene CYP24A1: a potential biomarker for colo-rectal tumorigenesis. J Histochem Cytochem 58:277-285.
5. Sharma V, Fretwell D, Crees Z, Kerege A, Klopper JP 2010 Thyroid cancer resistance to vitamin D receptor activation is associated with 24-hydroxylase levels but not the ff FokI polymorphism. Thyroid 20:1103-1111.
6. Lee S, Morimoto S, Onishi T, Tsuji M, Okada Y, Seino Y, Ishida M, Yamaoka K, Takai S, Miyauchi A, Kumahara Y 1982 Normal serum 1,25-dihydroxyvitamin D in patients with medullary carcinoma of the thyroid. J Clin Endocrinol Metab 55:361-363. (Pubitemid 13238742)
7. Stepien T, Krupinski R, Sopinski J, Kuzdak K, Komorowski J, Lawnicka H, Stepien H 2010 Decreased 1-25 dihydrox-yvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer. Arch Med Res 41:190-194.
8. Laney N, Meza J, Lyden E, Erickson J, Treude K, Goldner W 2010 The prevalence of vitamin D deficiency is similar between thyroid nodule and thyroid cancer patients. Int J Endocrinol 2010:805716.
9. Berg JP, Torjesen PA, Haug E 1993 1,25-dihydroxyvitamin D3 attenuates TSH and 8-(4-chlorophenylthio)-cAMP-stimulated growth and iodide uptake by rat thyroid cells (FRTL-5). Thyroid 3:245-251. (Pubitemid 23298930)
10. Lamberg-Allardt C, Valtonen E 1992 1,25-Dihydroxychol-ecalciferol attenuates thyrotropin stimulated iodide accu-mulation in rat thyroid follicular FRTL-5 cells by reducing iodide porter number. Biochem Biophys Res Commun 182: 1435-1439.
11. Khadzkou K, Buchwald P, Westin G, Dralle H, Akerstrom G, Hellman P 2006 25-hydroxyvitamin D3 1alpha-hydroxylase and vitamin D receptor expression in papillary thyroid car-cinoma. J Histochem Cytochem 54:355-361. (Pubitemid 43291280)